HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies.
about
Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure.Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals.Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman PrimatesElicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches.Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success.Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.Experimental Estimation of the Effects of All Amino-Acid Mutations to HIV's Envelope Protein on Viral Replication in Cell CultureEffects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction.Progress toward active or passive HIV-1 vaccination.One-step design of a stable variant of the malaria invasion protein RH5 for use as a vaccine immunogen.Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers.Germline-targeting immunogens.Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem.Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.Identification and specificity of broadly neutralizing antibodies against HIVTowards functional antibody-based vaccines to prevent pre-erythrocytic malaria infection.How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design.Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design.Hidden Lineage Complexity of Glycan-Dependent HIV-1 Broadly Neutralizing Antibodies Uncovered by Digital Panning and Native-Like gp140 Trimer.Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization.Comprehensive Mapping of HIV-1 Escape from a Broadly Neutralizing Antibody.Global site-specific N-glycosylation analysis of HIV envelope glycoprotein.Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity.What Are the Most Powerful Immunogen Design Vaccine Strategies? Reverse Vaccinology 2.0 Shows Great Promise.Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo.Current Peptide and Protein Candidates Challenging HIV Therapy beyond the Vaccine Era.Glycans Function as Anchors for Antibodies and Help Drive HIV Broadly Neutralizing Antibody Development.The 2017 Keystone Symposium on HIV Vaccines.HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage.Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding.Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens.Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers.Epitope-focused immunogens against the CD4-binding site of HIV-1 envelope protein induce neutralizing antibodies against auto- and heterologous viruses.Targeted Elimination of Immunodominant B Cells Drives the Germinal Center Reaction toward Subdominant Epitopes.Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows.Directed Evolution of Glycopeptides Using mRNA Display.Modulating the immune system through nanotechnology.Insights into the Structural Basis of Antibody Affinity Maturation from Next-Generation Sequencing.
P2860
Q30234773-F158E425-DD3A-4A7B-80C0-F8329BA764AAQ30490942-B2EB4626-1915-4AA0-9C0E-6C8846221D29Q33592001-49BE5DFD-0338-4C49-9256-9ECB959C088FQ33594304-90D587E8-6629-4C70-A416-11FE2E4D0A73Q33612459-701E9706-F32D-4060-B8E9-F38F6D5D9269Q33830824-3DE4923F-4E6E-4E30-BE60-222FA1EF64F7Q34550046-87B75B6C-78C6-41EF-B244-5F15C01DE33FQ34555891-38CA7350-0B7C-49DF-9FA7-A6BB8F29E1D5Q36222292-9D21F158-8FD9-4B22-BA63-D1441B8CA5DFQ36303368-B856738C-C208-41CA-A915-F166D3929A4DQ37549777-09C55309-04A0-4B24-A1FF-92F14D442F16Q37626240-0E26A5C6-7FBB-4554-B7BD-0D05A932D2E8Q37695592-07D0F162-068E-4E60-BD9D-F2DF01079CF4Q38764547-2EC523FA-66C5-4EC9-B84C-E9321626ABC7Q39108730-FF9A30F5-6962-4D8F-B6F2-68F384013214Q39108735-56F7E624-9603-4529-B3E3-9CF810624B80Q39108796-83EB2D71-A7E0-4D32-8B33-6C7E770E67E5Q39170404-AAB8F965-80D2-47A6-9CB6-4DDA2F7BA23CQ39250593-FBE2A264-8F2F-488A-9991-1E1413D8823AQ40043685-DE8D9884-E78F-4B42-9F43-51B3CD746297Q40061438-6AEC78B7-870B-4E28-B228-8E95F0AC657AQ40073525-338DB562-441A-478E-BE7A-99F7DA5AAC5FQ40173474-C194D2A8-8DC6-4148-AE51-A1AFF29D1382Q40276435-21B5684B-90F3-4073-BF71-7F6570F0DA00Q40301176-B9887022-47C0-4E5C-B4F6-6A5FE2EDA5F6Q40346058-D1ECD71E-E653-4A60-AEA3-432ABCF570EDQ41611835-BF2EAF08-CF7F-4CE7-95EF-83544F64460DQ41928050-354F7122-8B8E-41C3-8497-A1F66B4F49C5Q41936503-513843BB-74FD-4A2A-8ABA-8C2788C67C41Q46104275-21594F0F-408D-493A-A18A-67EB8C3E1258Q46454115-8E7EB8AC-2BEE-4770-9DFA-62766DBA27B6Q46631754-B4600EF6-5336-4075-B100-4ED922253B61Q47232975-3C45EE54-F601-410D-A173-1C283579CD7CQ47313525-6F4FCD57-556B-432C-85CA-5BC2FBB5F2BBQ47349916-EB98CFEB-9D33-4FA8-9FC8-22A894DFB215Q47560170-6E969FB3-5293-4D17-BBDD-9E5688E5F6A7Q47700206-6A0F82E8-603D-4FFB-8CCE-B682F69937D3Q47765958-CCBD62F1-2187-4740-900E-3EBAD17AA27DQ48630939-4C8414E4-57D7-4371-BB25-681E87255F11Q49956907-8C7583B8-A7A8-4CA9-A85E-D128A921BD59
P2860
HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 September 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
HIV Vaccine Design to Target G ...... oadly Neutralizing Antibodies.
@en
HIV Vaccine Design to Target G ...... oadly Neutralizing Antibodies.
@nl
type
label
HIV Vaccine Design to Target G ...... oadly Neutralizing Antibodies.
@en
HIV Vaccine Design to Target G ...... oadly Neutralizing Antibodies.
@nl
prefLabel
HIV Vaccine Design to Target G ...... oadly Neutralizing Antibodies.
@en
HIV Vaccine Design to Target G ...... oadly Neutralizing Antibodies.
@nl
P2093
P2860
P1433
P1476
HIV Vaccine Design to Target G ...... oadly Neutralizing Antibodies.
@en
P2093
Alexander D Gitlin
Amelia Escolano
Andrew A Mutafyan
Andrew B Ward
Bryan Briney
Christian T Mayer
Daniel W Kulp
Darrell J Irvine
Dennis R Burton
Dong Soo Yun
P2860
P304
P356
10.1016/J.IMMUNI.2016.08.016
P407
P577
2016-09-07T00:00:00Z